滤泡性淋巴瘤 (FL) 是非霍奇金淋巴瘤的第二常见亚型，其生存和进展依赖于与肿瘤微环境中的免疫元件（包括滤泡辅助 T 细胞和滤泡树突状细胞）的相互作用。尽管 FL 最初对化学免疫疗法有反应，但通常认为无法治愈。改善免疫介导的 FL 控制的策略可以使这一人群显着受益，特别是因为它包括许多老年和合并症患者。免疫细胞接合剂，尤其是双特异性抗体 (BsAb)，对于通过桥接肿瘤和效应细胞来靶向 FL 至关重要，从而触发 T 细胞激活和细胞毒性杀伤。 CD3 × CD20 BsAb 在 B-NHL 患者的临床开发中显示出最大的前景，其结构变化会影响其靶点亲和力和效力。本综述总结了目前双特异性抗体治疗复发/难治性 FL 的临床试验，重点介绍了一些药物的批准、它们在一线治疗或联合治疗中的作用、它们的毒性特征，以及与其他免疫细胞疗法相比这种治疗方法的未来.© 2024 作者。经泰勒许可出版

Follicular lymphoma (FL), the second most common subtype of non-Hodgkin lymphoma, relies on interactions with immune elements in the tumor microenvironment, including T-follicular helper cells and follicular dendritic cells, for its survival and progression. Despite its initial responsiveness to chemoimmunotherapy, FL is generally considered incurable. Strategies to improve immune-mediated control of FL could significantly benefit this population, particularly as it includes many elderly and comorbid patients. Immune cell engagers, especially bispecific antibodies (BsAbs), are crucial in targeting FL by bridging tumor and effector cells, thereby triggering T-cell activation and cytotoxic killing. CD3 × CD20 BsAbs have shown the most promise in clinical development for B-NHL patients, with structural variations affecting their target affinity and potency. This review summarizes the current clinical trials of BsAbs for relapsed/refractory FL, highlighting the approval of some agents, their role in first-line treatment or combination therapies, their toxicity profiles, and the future of this therapeutic approach compared to other immune cell therapies.© 2024 The Author(s). Published with license by Taylor & Francis Group, LLC.